Record Number of Publications
The company saw a record number of third-party publications, demonstrating the value of the Proteograph and further validating its performance across a range of applications.
Increased Instrument Shipments
In the first 9 months of 2025, the company shipped just under 3x as many instruments as in all of 2024, reflecting strong demand for the Proteograph.
Large-Scale Study with Korea University
Initiated a 20,000 sample population study with Korea University and a 10,000 sample project with Discovery Life Sciences.
High Customer Engagement
Overwhelmingly positive customer feedback on the Proteograph ONE Assay and SP200 Automation Instrument, with strong demand and utilization observed in the first few months post-launch.
First Joint Sale with Thermo Fisher
Received the first joint sale from the partnership with Thermo Fisher, indicating progress in the collaboration.
Share Repurchase Program
Repurchased approximately $22 million of Class A common shares, reducing net total shares outstanding by approximately 14%.